Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 574
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT03613298 Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endome… |
HIFU (Focal One®) | Cancer | Non applicable | COMPLETED | En attente / non publié | EDAP TMS S.A. | France · Hôpital de la Croix Rousse, Lyon, France | 2015-09-21 → 2019-05 | Ouvrir |
| NCT05512663 Safety and Efficacy Evaluation of Transperineal Irreversible Electropor… |
Irreversible Electroporation (IRE) | Cancer | Non applicable | UNKNOWN | En attente / non publié | Jewish General Hospital | Non communiqué | 2022-09 → 2024-09 | Ouvrir |
| NCT07766252 CCHW-delivered CFH-based Cancer Prevention Program Among Chinese Americ… |
CCHW-delivered CFH-based Cancer P… | Cancer | Non applicable | COMPLETED | En attente / non publié | Texas A&M University | United States · Texas A&M University, College Station… | 2019-12-01 → 2020-12-31 | Ouvrir |
| NCT06743555 SAVED LUNG — Surgery After Verifying Existing Disease in Locally Advanc… |
Standard-of-care surgery | Cancer | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Centre hospitalier de l'Universit… | Canada · Centre Hospitalier de l'Universite de Montre… | 2026-10-01 → 2032-02 | Ouvrir |
| NCT05691478 A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy i… |
Bone Scan | Cancer | Phase 2/3 | SUSPENDED | En attente / non publié | National Cancer Institute (NCI) | United States, Australia, Canada, New Zealand · Adven… | 2023-03-03 → 2030-03-20 | Ouvrir |
| NCT07388524 Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery … |
Atezolizumab | Cancer | Phase 3 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Abbott-Northwestern Hospital, Minneap… | 2027-03-02 → 2032-09-30 | Ouvrir |
| NCT07281417 Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment… |
Biopsy Procedure | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Emory University Hospital Midtown, At… | 2026-11-24 → 2030-12-16 | Ouvrir |
| NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lym… |
MK-1045 | Cancer | Phase 2/3 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Israel, Spain, Taiwan, Turk… | 2026-06-22 → 2035-07-23 | Ouvrir |
| NCT06406465 A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Tox… |
Belinostat | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2026-08-19 → 2028-07-30 | Ouvrir |
| NCT05904899 An Evaluation of the Implementation of the Care and Monitoring at Home … |
An Evaluation of the Implementati… | Cancer | À vérifier | SUSPENDED | En attente / non publié | M.D. Anderson Cancer Center | United States · MD Anderson Cancer Center, Houston, U… | 2023-08-01 → 2026-12-31 | Ouvrir |
| NCT07733908 Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Pros… |
Effectiveness of Posluma PET Scan… | Cancer | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Aditya Bagrodia | Non communiqué | 2026-08 → 2030-07 | Ouvrir |
| NCT03436485 CYPIDES — Safety and Pharmacokinetics of ODM-208 in Patients With Metas… |
ODM-208 | Cancer | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Orion Corporation, Orion Pharma | United States, Finland, France, United Kingdom · Cent… | 2018-03-19 → 2026-10-31 | Ouvrir |
| NCT06050252 Testing the Combination of the Anticancer Drug Durvalumab With Chemothe… |
Biopsy Procedure | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Boston Medical Center, Boston, United… | 2024-07-10 → 2027-02-12 | Ouvrir |
| NCT05904782 Development of Brief Positive Affect Treatment (PAT) for Caregivers of … |
Development of Brief Positive Aff… | Cancer | À vérifier | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · The University of Texas M. D. Anderso… | 2025-08-29 → 2027-11-01 | Ouvrir |
| NCT05844865 Patient Derived Vascularized MicroTumor Model of Gastrointestinal Perit… |
Patient Derived Vascularized Micr… | Cancer | Non applicable | RECRUITING | En attente / non publié | University of California, Irvine | United States · Chao Family Comprehensive Cancer Cent… | 2023-05-04 → 2026-12 | Ouvrir |
| NCT06409065 Psycho-Spiritual Management for Patients With Advanced Cancer and Their… |
Psycho-Spiritual Management for P… | Cancer | Non applicable | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · MD Anderson, Houston, United States | 2024-01-09 → 2028-08-31 | Ouvrir |
| NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo P… |
Adagrasib | Cancer | Phase 3 | RECRUITING | En attente / non publié | Mirati Therapeutics Inc. | United States, Argentina, Australia, Austria, Belgium… | 2025-04-24 → 2032-04-30 | Ouvrir |
| NCT04858958 FAVOUR — Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 I… |
Furmonertinib 160mg | Cancer | Phase 1 | COMPLETED | En attente / non publié | Allist Pharmaceuticals, Inc. | China · Shanghai Chest hospital, Shanghai, China | 2020-08-10 → 2025-06-25 | Ouvrir |
| NCT07764887 Impacted Tooth Management and Osteoradionecrosis Risk in NPC |
Prophylactic Impacted Tooth Extra… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | First Affiliated Hospital of Guan… | China · Affiliated Hospital of Youjiang Medical Unive… | 2026-08-30 → 2032-11-30 | Ouvrir |
| NCT07764744 OC-LEAD — Ovarian Cancer Liquid Biopsy for Early Assessment & Detection… |
Galleri Multi-Cancer Early Detect… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Weill Medical College of Cornell … | United States · MD Anderson Cancer Center, Houston, U… | 2026-08 → 2039-07 | Ouvrir |
| NCT05864534 Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblas… |
Balstilimab | Cancer | Phase 2 | RECRUITING | En attente / non publié | Northwestern University | United States · Northwestern University, Chicago, Uni… | 2024-01-19 → 2031-08-31 | Ouvrir |
| NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Car… |
carboplatin | Cancer | Phase 2 | RECRUITING | En attente / non publié | Bristol-Myers Squibb | United States · Atrium Health Levine Cancer Institute… | 2025-11-21 → 2030-02 | Ouvrir |
| NCT04305041 Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With … |
Pembrolizumab | Parkinson | Phase 1/2 | COMPLETED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Australia, France, Israel, Italy, Sout… | 2020-06-26 → 2025-08-25 | Ouvrir |
| NCT03076554 A Pilot Study to Investigate the Safety and Clinical Activity of Avelum… |
Avelumab | Parkinson | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2017-04-19 → 2028-03-30 | Ouvrir |
| NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in C… |
Sacituzumab Tirumotecan | Parkinson | Phase 3 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Australia, Belgium, Brazil,… | 2024-04-14 → 2031-04-12 | Ouvrir |